Evidence map›Paper›PMID 42771268›Full record

ArticleJournal of pharmacokinetics and pharmacodynamics2026

Development of an isavuconazole physiologically-based pharmacokinetic model for adult and pediatric populations.

Mary P Choules, Amit Desai, Laura Lynn Kovanda, Yukio Otsuka, Roger J Brüggemann, Peter L Bonate

Abstract read
In one paragraph

Article in Journal of pharmacokinetics and pharmacodynamics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mary P ChoulesAstellas Pharma Global, Inc, 2375 Waterview Dr, Northbrook, IL, 60062, USA. mary.choules@astellas.com.ORCID http://orcid.org/0000-0003-1771-3245
Amit DesaiAstellas Pharma Global, Inc, 2375 Waterview Dr, Northbrook, IL, 60062, USA.ORCID http://orcid.org/0000-0001-7394-3606
Laura Lynn KovandaAstellas Pharma Global, Inc, 2375 Waterview Dr, Northbrook, IL, 60062, USA.ORCID http://orcid.org/0000-0002-4493-4652
Yukio OtsukaAstellas Pharma, Inc, Tokyo, Japan.
Roger J BrüggemannDepartment of Pharmacy, Pharmacology and Toxicology, and Radboudumc- CWZ Center of Expertise in Mycology, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID http://orcid.org/0000-0002-7618-725X
Peter L BonateAstellas Pharma Global, Inc, 2375 Waterview Dr, Northbrook, IL, 60062, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Isavuconazonium sulfate is the water-soluble prodrug of the active triazole antifungal agent isavuconazole. Isavuconazonium sulfate is approved for the treatment of invasive aspergillosis and invasive mucormycosis in pediatric and adult populations. In the present analysis, an isavuconazole physiologically-based pharmacokinetic (PBPK) model was built and verified in adult and pediatric populations using the Simcyp

Indexed as

Antifungal AgentsModels, BiologicalNitrilesPyridinesTriazolesAdolescentAdultArea Under CurveChildChild, PreschoolComputer SimulationDrug InteractionsFemaleHumansInfantMaleAntifungal AgentsisavuconazoleNitrilesPyridinesTriazolesAntifungalDrug-drug interaction (DDI)IsavuconazolePediatric DDIPhysiological-based pharmacokinetics (PBPK)Simcyp

Identifiers

PMID42771268
PMCPMC13597547

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.